Xeris (XERS) CMO receives 121K RSUs and 162K options in equity grant

Rhea-AI Filing Summary

Xeris Biopharma Holdings Chief Medical Officer Nguyen Anh Tu reported new equity awards. On January 30, 2026, he received 121,293 shares of common stock through a restricted stock unit grant and 162,162 stock options with a $7.36 exercise price.

The restricted stock units and stock options each vest in equal annual installments over three years, conditioned on continued employment or service. Following the grant, he directly holds 424,323 shares of common stock and 162,162 options, plus indirect holdings of common stock through an IRA and a children's IRA, for which he disclaims beneficial ownership beyond his economic interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nguyen Anh Tu

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		121,293(1)	A	$0	424,323(2)	D
Common Stock								3,710(3)	I	By IRA
Common Stock								3,501(3)	I	By children's IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.36	01/30/2026		A		162,162		(4)	01/30/2036	Common Stock	162,162	$0	162,162	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.

2. Includes 3,030 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

4. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

Chief Medical Officer

	/s/ Beth Hecht, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did XERS report for Nguyen Anh Tu?

Xeris Biopharma’s Chief Medical Officer Nguyen Anh Tu reported receiving new equity awards. He was granted 121,293 restricted stock units and 162,162 stock options on January 30, 2026, both vesting over three years, reflecting part of his long-term incentive compensation package.

How many XERS restricted stock units were granted to Nguyen Anh Tu?

Nguyen Anh Tu received 121,293 restricted stock units in Xeris Biopharma common stock. Each unit represents a right to one share and vests in equal annual installments over three years, contingent on his continued employment with the company during the vesting period.

What are the terms of the XERS stock options granted to Nguyen Anh Tu?

He was granted 162,162 stock options with a $7.36 exercise price. These options vest in equal annual installments over three years, subject to continued service, and are exercisable for Xeris Biopharma common stock until their stated expiration date in 2036.

How many XERS shares does Nguyen Anh Tu own after the reported grants?

After the grants, he directly holds 424,323 shares of Xeris Biopharma common stock. He also has indirect holdings through an IRA and a children’s IRA, for which he disclaims beneficial ownership except to the extent of his pecuniary interest in those accounts.

What XERS equity plans were used for Nguyen Anh Tu’s awards?

The restricted stock units and stock options were issued under Xeris Biopharma’s 2018 Stock Option and Incentive Plan. Additionally, his total shares include 3,030 shares acquired on December 31, 2025 under the company’s 2018 Employee Stock Purchase Plan, as amended.

Does Nguyen Anh Tu fully own the XERS shares held in IRA accounts?

The filing states he disclaims beneficial ownership of the IRA and children’s IRA shares except for his pecuniary interest. This means he reports them but does not admit full beneficial ownership of all such shares for Section 16 or other legal purposes.